Tag: Boston Scientific

Boston Scientific announces agreement to acquire Devoro Medical

Today, Boston Scientific announced an agreement to acquire Devoro Medical, developer of the Wolf thrombectomy platform. The non-console and lytic-free Wolf technology targets and...

Boston Scientific initiates randomised controlled trial for the EkoSonic endovascular system

Boston Scientific has commenced enrolment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the...

Boston Scientific and BD initiate venous stent recalls

Boston Scientific and BD have both initiated recalls of venous stents. According to a US Food and Drug Administration (FDA) medical device recall notice...

Long-term data revealed for VICI Venous Stent System

Michael Lichtenberg (Karolinen Hospital, Arnsberg, Germany) details three-year data from the Arnsberg venous registry on the VICI Venous Stent System (Boston Scientific). This video forms...
Michael Lichtenberg

Three-year data add to growing body of clinical evidence in support...

This advertorial is sponsored by Boston Scientific. The VICI Venous Stent System (Boston Scientific) is associated with excellent primary patency rates, with concomitant symptomatic improvement...

Three-year data add to growing body of clinical evidence in support...

The VICI Venous Stent System (Boston Scientific) is associated with excellent primary patency rates, with concomitant symptomatic improvement in Clinical-Etiological-Anatomical-Pathophysiological (CEAP) classification, directly after...

Boston Scientific receives US FDA approval for the Vici Venous Stent...

Boston Scientific has announced hat the US Food and Drug Administration (FDA) has approved the Vici venous stent system for the treatment of iliofemoral...

VIRTUS subanalysis identifies correlates to improved patient outcomes after venous stenting

 Mahmood Razavi (Orange, USA) reported new data from a subanalysis of the VIRTUS trial, which set out to investigate the safety and efficacy of...

VIRTUS 12-month outcomes presented at LINC: Vici stent meets primary endpoints

New 12-month data from the VIRTUS trial demonstrates that patients who were treated with the Vici Venous Stent system (Boston Scientific) for iliac and femoral...

Boston Scientific announces recommended offer to acquire BTG

Boston Scientific has announced it has reached an agreement on the terms of a recommended offer to acquire BTG, a company headquartered in the...

Boston Scientific announces agreement to acquire Veniti

Boston Scientific has signed an agreement to acquire Veniti, a privately-held company in Fremont, USA which developed and commercialised the Vici venous stent system for...

Veniti announces Boston Scientific distribution agreement for Vici venous stent

Boston Scientific will distribute Veniti’s Vici venous stent under a limited global distribution agreement. The terms of the agreement and specific regions and countries...

Endovenous laser therapy of saphenous vein reflux using thulium laser with...

In this clinical study the one-year results of the endovenous laser therapy (ELT) application of 1,940nm laser (Vela XL, Boston Scientific) with respect to...

Veniti closes on US$25m from Boston Scientific

Veniti has closed on US$25m in Series D equity financing from Boston Scientific Corporation. The funds will allow Veniti to complete the VIRTUS trial...